Biofrontera Inc. announces notice of allowance for nanoemulsion patent

Biofrontera Inc. announced that the United States Patent and Trademark Office has granted a notice of allowance to Biofrontera Bioscience GmbH for patent application No. 12/520,759, titled "Nanoemulsion Formulation with Improved Stability and Cell Penetration." Biofrontera Inc. has an exclusive license to market and sell Ameluz, an FDA-approved drug utilizing the technology covered by the patent, in the U.S. The '759 patent relates to the compositions of Biofrontera's nanoemulsions and an active agent and the preparation of the nanoemulsions or compositions, and describes its use in the treatment of dermatological, virus-associated and cell proliferation diseases, as well as in cosmetics. Biofrontera's compositions of nanoemulsions overcome the disadvantages of other nanoemulsion formulations through a reduced particle size that contributes to improved stability, better penetration into cells and tissues and lower production costs. "This new patent will further protect Biofrontera's growing position in the dermatology market and our continued investment in the market. Compound-of-matter patents provide the strongest protection of all patent types. Our license agreement covers all combinations of the patented nanoemulsion technology with aminolevulinic acid, the active ingredient in Ameluz. Together with Biofrontera Bioscience we are now even more strongly positioned to broaden the use of photodynamic therapy in dermatology," stated Hermann Lubbert, Executive Chairman of Biofrontera Inc.